D uring the past 3 decades, advancements in drug and devicebased therapy have substantially improved survival and quality of life for ambulatory patients with chronic heart failure (HF) with reduced ejection fraction (EF). 1 However, there has been limited progress for patients hospitalized with acute HF (AHF) and combined rates of death and readmission remain as high as 40% within 90 days of discharge. 2 Several large, international trials have investigated various treatments in the AHF population, but all have failed to definitively improve clinical outcomes. [3] [4] [5] [6] Multiple reasons for lack of trial success have been proposed, but increasing attention is being directed toward study execution and trial site performance. 7, 8 Site Enrollment and Trial Performance event rates and detection of therapeutic efficacy. [7] [8] [9] However, despite these concerns, there are limited data systematically evaluating associations between site enrollment, patient profile, protocol completion, and trial end points. 10, 11 Moreover, in light of well-documented heterogeneity within AHF trials across global regions, it is plausible that any influence of site enrollment could vary by the specific region of enrollment. 12, 13 Thus, a more nuanced understanding of such relationships could have important and practical implications for interpreting and optimizing future trials. In this context, the global ASCEND-HF database (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) provides an opportunity to rigorously characterize the correlation between site enrollment rate, patient characteristics, protocol completion, and AHF trial end points.
Methods

Study Design
The study design and results of the ASCEND-HF trial have been previously reported. 5, 14 Briefly, ASCEND-HF was a prospective, multinational, randomized, placebo-controlled trial studying the effects of nesiritide, an intravenous recombinant B-type natriuretic peptide, on dyspnea relief and clinical outcomes among patients hospitalized for AHF. Eligible patients were enrolled within 24 hours of first intravenous HF therapy and had dyspnea at rest or with minimal exertion, ≥1 clinical sign of HF, and ≥1 objective measure of HF. Informed consent was obtained from all patients. The trial was conducted in full accordance with the Declaration of Helsinki and with institutional review board/ethics committee approval at all sites.
Clinical Trial Sites
The ASCEND-HF trial enrolled 7141 patients at 398 sites across 30 countries in North America, Latin America, Western Europe, Central Europe, and Asia-Pacific between May 2007 and August 2010. Per study protocol, geographic regions were defined as the following: North America: Canada and United States; Latin America: Argentina, Brazil, Chile, Colombia, and Mexico; Western Europe: France, Germany, Greece, Israel, Italy, the Netherlands, and Norway; Sweden; Central Europe: Bulgaria, Lithuania, Poland, Romania, Russia, and Ukraine; Asia-Pacific: Australia, China, India, Malaysia, New Zealand, Republic of Korea, Singapore, Taiwan, and Thailand.
Study End Points and Definitions
The prespecified end points for the present study were (1) composite 30-day all-cause death or HF hospitalization, (2) composite 30-day allcause death or all-cause rehospitalization, (3) 180-day all-cause death, and (4) persistent dyspnea (ie, no dyspnea improvement) at 6 and 24 hours. An independent blinded clinical events committee adjudicated all causes of death and hospitalization within 30 days (University of Glasgow, Glasgow, Scotland, UK). To evaluate trial site performance, protocol noncompletion rate at 180 days represented an additional end point. Protocol noncompletion was defined as early withdrawal from the study due to withdrawal of consent, lost to follow-up, or protocol deviation. To be consistent with a previous analysis, a modified definition of protocol noncompletion with additional inclusion of early withdrawal because of death or adverse events was tested in sensitivity analysis. 10 Persistent dyspnea was defined using a self-reported 7-point categorical Likert scale as markedly worse, moderately worse, minimally worse, no change, or minimally better. Definitions for protocol deviation and hospitalization for HF are provided in Appendix A in the Data Supplement.
Statistical Analysis
For descriptive purposes, patients were assigned to 1 of 4 enrollment volume groups defined by the overall enrollment of their respective trial site (ie, 1-19 patients, 20-39 patients, 40-60 patients, >60 patients). These cut points were chosen a priori based on the distribution of patients across varying site enrollment (ie, ≈25% of overall trial population was from sites enrolling <18 patients and >59 patients, respectively) and for ease of communication (ie, intervals of ≈20 patients). Baseline characteristics were compared across groups. Continuous variables were reported as median (quartile 1 and quartile 3) and compared using the Kruskall-Wallis tests. Categorical variables were presented as frequencies and percentages and compared using the Pearson χ 2 test or the Fisher exact test. Survival distributions and event rates were compared across groups using the Kaplan-Meier method.
Unadjusted and adjusted logistic regression models were constructed to evaluate associations between site enrollment volume and 30-day end points and persistent dyspnea. Unadjusted and adjusted Cox models were used to evaluate associations with 180-day all-cause death. To account for potential clustering of patients and sites within countries which may be correlated with site enrollment volume and outcomes, multilevel models were used. Specifically, random-intercept, multilevel logistic regressions (generalized linear mixed models) and shared frailty Cox regression, each using random effects for country of enrollment, were utilized. Adjusted models included 17 prespecified variables either previously utilized in ASCEND-HF mortality and dyspnea models or added per clinical judgment. 15, 16 Because of lack of established confounders, protocol noncompletion was evaluated using an unadjusted model only. Linearity and proportional hazards assumptions were tested with all models. No violations were found with exception of linearity violation for protocol noncompletion, necessitating addition of 2 linear splines to the model, and the final model included only the significant piece. As mentioned, sensitivity analysis was performed using a modified definition of protocol noncompletion that included death and adverse events. The multiple imputation was used for missing covariate data; results reflect the combined analysis of 25 imputed data sets. All statistical analyses were performed using SAS version 9.2 or later (SAS Institute, Cary, NC). Two-tailed P<0.05 was considered statistically significant.
Results
Distribution of Site Enrollment
Of the 398 trial sites that enrolled ≥1 participant, 274 sites (68.8%) enrolled 1 to 19 patients, 87 sites (21.9%) enrolled 20 to 39 patients, 20 sites (5.0%) enrolled 40 to 60 patients, and 17 sites (4.3%) enrolled >60 patients. These groups comprised 2152, 2285, 923, and 1781 patients, respectively. The median site enrollment was 12 patients (interquartile range, 5-23). The proportion of patients (P<0.001) and sites (P=0.002) within each enrollment group differed by geographic region ( Table I in the Data Supplement). For example, ≈50% of patients from Asia-Pacific were recruited from sites enrolling >60 patients, whereas there were no such high enrolling centers in Western Europe.
Patient Characteristics
Baseline patient characteristics varied widely by site enrollment group (Table 1) . Patients from sites enrolling >60 participants tended to be younger and were less likely to be white and from North America. This group had the lowest median EF and was most likely to have New York Heart Association Class III/IV symptoms. Multiple vital sign and laboratory markers tracked with the high enrollment group, including lower systolic blood pressure, body mass index, hemoglobin, and serum sodium and higher heart rate and blood urea nitrogen. Despite having the highest prevalence of reduced EF patients, use of β-blockers, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, mineralocorticoid receptor antagonist, implantable cardioverter-defibrillators, and cardiac resynchronization therapy were lowest among patients in the high enrollment group. In contrast to these higher risk features, patients from high enrolling centers had the lowest median B-type natriuretic peptide level and generally carried fewer comorbidities.
Protocol Completion
Increasing site enrollment was associated with reduced likelihood of protocol noncompletion (odds ratio [OR], 0.93; 95% confidence interval [CI], 0.89-0.98; P=0.003, per 10 patient increase in enrollment volume up to 100 patients). Sensitivity analysis using a modified definition of protocol noncompletion (including death and adverse events as protocol noncompletion) yielded similar results (OR, 0.95; 95% CI, 0.93-0.97; P<0.001). Data for individual components of protocol noncompletion are displayed in Table 2 .
Trial End Points
Kaplan-Meier event rates by enrollment volumes are displayed in Table 3 and Figure 2 . Sites enrolling >60 patients and 1 to 19 patients had the lowest and highest rates of 30-day all-cause death or HF hospitalization at 8.11% and 11.28%, respectively (P=0.016). Sites with higher enrollment volume tended to have lower rates of 30-day HF hospitalization, 30-day all-cause hospitalization, and 180-day death (all P≤0.011). Rates of 30-day all-cause death were not significantly different between groups.
Unadjusted and adjusted outcome analyses for trial end points are presented in Table 4 . Every 10 patient increase in site enrollment was associated with significantly lower risk of 30-day all-cause death or rehospitalization (OR, 0.98; Data expressed as n (%) or median (interquartile range). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable cardioverter-defibriilator; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; and PCI, percutaneous coronary intervention.
*Overall, 5477 patients had precise ejection fraction measurement data. All 7141 patients had data for ejection fraction ≥ or <50%. †5893 patients had data available for New York Heart Association class. ‡There were 6592, 6682, 6595, and 6757 total patients with available hemoglobin, sodium, BUN, and creatinine data, respectively. §There were 4501 and 990 patients with available NT-proBNP and BNP data, respectively. In both unadjusted and adjusted analyses, site enrollment was predictive of persistent dyspnea. However, the nature of this relationship differed by timing of dyspnea assessment. Higher site enrollment was independently associated with greater risk of persistent dyspnea at 6 hours (OR, 1.02; 95% CI, 1.01-1.03; P<0.001) but a trend toward lower risk at 24 hours (OR, 0.99; 95% CI, 0.98-1.00; P=0.080).
Discussion
In this large, multinational, AHF trial, there was wide variation in patient enrollment volume across participating sites, and patients from higher enrolling sites were more likely to complete the study protocol. Increasing site enrollment correlated with lower risk of postdischarge death and repeat hospitalization and, after adjustment, was independently associated with lower risk of 30-day death or rehospitalization. Increasing site enrollment independently predicted likelihood of persistent dyspnea, but the relationship differed by timing of dyspnea assessment.
To our knowledge, the only previous analysis of site enrollment from an AHF drug trial comes from the EVEREST trial (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan). 10 Similar to the present study, enrollment from higher enrolling centers independently predicted more favorable postdischarge outcomes. However, these data from ASCEND-HF offer several novel features that add incremental and more granular insight into the role of site enrollment in AHF studies. First, in contrast to the EVEREST analysis, the statistical approach of the present study used continuous variable outcome analysis to avoid potential bias from defining enrollment groups with arbitrary cut points. Linearity was confirmed across the entire range of site enrollment volume. Combined with a higher median enrollment rate in ASCEND-HF (ie, 12 patients per site versus 6 patients per site in EVEREST) that allowed assessment over a broader range of enrollment volume, the present findings offer more generalizability to future HF drug development programs. 10 Second, the present study is the first to document the relationship between site enrollment volume and dyspnea-related trial end points. Third, ASCEND-HF included a subset of patients with preserved EF, whereas EVEREST was limited to EF ≤40%. Fourth, although numeric data for early protocol termination were provided in the EVEREST article, we document a statistically significant relationship between site enrollment volume and rates of protocol noncompletion and tested both inclusion and exclusion of death and adverse events within a composite protocol noncompletion definition. Last, we document, for the first time, a positive interaction between geographic region, site enrollment, and clinical outcomes.
As mentioned, we present the first data evaluating the influence of site enrollment on patient-reported dyspnea. Dyspnea is the most common presenting symptom of AHF and is recognized by regulatory agencies as an efficacy end point for AHF trials. 17, 18 However, despite strong rationale for a dyspnea outcome measure, multiple issues may influence a trial's ability to meet such an end point, including timing of dyspnea assessment relative to presentation, method of dyspnea measurement, and lack of a standardized definition. 17, 18 The present data support trial site enrollment as another potential confounder. Moreover, differing influence of site enrollment on dyspnea measured at 6 versus 24 hours would further support importance of dyspnea assessment timing in study design. It remains unclear why increasing site enrollment in ASCEND-HF conferred heightened risk of persistent dyspnea at 6 hours but a trend toward lower risk at 24 hours. Although this could represent a chance finding, one may speculate differences in timing or dosing of initial standard AHF therapies that track with enrollment volume across trial sites.
Notably, the influence of site enrollment on clinical outcomes differed by geographic region. Such regional differences were not seen in the aforementioned EVEREST analysis. 10 The current findings add further context to the growing number of examples of global heterogeneity within HF trials and suggest a primary mechanism by which geographic region may influence study end points. 19, 20 Clinical Trial Implications
The heterogeneity of the HF syndrome and of the populations enrolled in international AHF clinical trials has been posited as a main reason for failure of drug development programs. 7, 21, 22 The present data support site enrollment volume as an important additional domain of AHF trial heterogeneity that has implications for future study design, execution, and costs. Despite strict and uniform trial selection criteria, patients from sites of varying enrollment are markedly different and at differing risk of trial end points, even after adjustment for conventional risk factors and demographics. These findings suggest existence of strong selection biases across sites and geographic regions, potentially mediated by differing interpretations of inclusion criteria and varying quality of local recruitment infrastructures. Alternatively, systematic differences in in-hospital and postdischarge care could track with site enrollment rate and influence outcomes. Although we found no suggestion of differing nesiritide effect by site enrollment volume, it remains highly plausible that, given influences on patient profile and outcome, site enrollment Although the ideal enrollment volume remains largely trial specific and a balance of multiple factors, these findings from ASCEND-HF support consideration of prespecified site enrollment targets. Indeed, absolute enrollment volumes may be less important than degree of variation in enrollment across sites. The current data suggest that standardized enrollment volume may represent an objective marker of a more uniform In addition, upfront knowledge of the expected number of patients per site would facilitate more accurate determination of the necessary number of centers, potentially excluding sites that do not justify the costs of site training and maintenance. 9 Utilization of previously described pretrial registries and pragmatic trial designs using electronic health records may be the most efficient means of identifying sites capable of meeting prespecified enrollment targets. 9, 23 Limitations Although rigorous multivariate modeling was performed, the retrospective observational nature of the current study prohibits definitive determination of cause-effect relationships. Second, despite statistical significance, the magnitude of risk represented by the ORs in this study was generally small. However, CIs were narrow, supporting a high degree of precision. Moreover, relative risks represent 10 patient increments in enrollment volume, and thus magnitude of risk would be substantially higher if comparing low and high enrolling centers, for example. Third, data on additional site characteristics were not available, including center size, academic versus nonacademic, teaching versus nonteaching, and rural versus urban location. Fourth, the definition of protocol deviation was relatively specific in ASCEND-HF (Appendix A in the Data Supplement), and the current study should not imply that all forms of protocol deviation uniformly necessitate patient withdrawal from clinical trials.
Conclusions
In this large AHF trial, there was wide variation in enrollment volume across study sites. Patient characteristics and utilization of guideline therapies varied by level of site enrollment. Increased site enrollment volume correlated with improved rates of protocol completion and was independently associated with trial end points. Individual and regional site performance present challenges that should be considered in design of future AHF trials.
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